secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2025-03-14T23:59:59+00:00
Accession:  0001023024-25-000021
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharmaceuticals receives FDA approval to expand ILUVIEN label for chronic non-infectious uveitis
--------------------------------------------------------------------------------

- FDA approved ILUVIEN for chronic non-infectious uveitis affecting posterior segment (NIU-PS), expanding beyond DME.
- ANI plans to market ILUVIEN under the combined label in the U.S. later this year.
- Extended supply agreement with Siegfried through 2029; equipment upgrade and capacity expansion planned.
- ILUVIEN is already approved for both DME and NIU-PS in 17 European countries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302425000021/0001023024-25-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302425000021/ani-20250314.htm
  HTML page:      https://secwatch.observer/filing/0001023024-25-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer